Search

Your search keyword '"Linda S. Lindström"' showing total 3 results
Start Over Author "Linda S. Lindström" Publisher bmc
3 results on '"Linda S. Lindström"'

1. Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients

Author

Miguel Castresana-Aguirre, Annelie Johansson, Alexios Matikas, Theodoros Foukakis, Linda S. Lindström, and Nicholas P. Tobin

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The clinical utility of gene signatures in older breast cancer patients remains unclear. We aimed to determine signature prognostic capacity in this patient subgroup. Methods Research versions of the genomic grade index (GGI), 70-gene, recurrence score (RS), cell cycle score (CCS), PAM50 risk-of-recurrence proliferation (ROR-P), and PAM50 signatures were applied to 39 breast cancer datasets (N = 9583). After filtering on age ≥ 70 years, and the presence of estrogen receptor (ER) and survival data, 871 patients remained. Signature prognostic capacity was tested in all (n = 871), ER-positive/lymph node-positive (ER + /LN + , n = 335) and ER-positive/lymph node-negative (ER + /LN−, n = 374) patients using Kaplan–Meier and multivariable Cox-proportional hazard (PH) modelling. Results All signatures were statistically significant in Kaplan–Meier analysis of all patients (Log-rank P

Published
2024
Full Text
View/download PDF

2. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours

Author

Arian Lundberg, Linda S. Lindström, Jingmei Li, J. Chuck Harrell, Eva Darai-Ramqvist, Emmanouil G. Sifakis, Theodoros Foukakis, Charles M. Perou, Kamila Czene, Jonas Bergh, and Nicholas P. Tobin

Subjects
CCND1 gene amplification, Gene expression, Breast cancer, PAM50, Luminal A, CDK4/6, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Use of cyclin D1 (CCND1) gene amplification as a breast cancer biomarker has been hampered by conflicting assessments of the relationship between cyclin D1 protein levels and patient survival. Here, we aimed to clarify its prognostic and treatment predictive potential through comprehensive long-term survival analyses. Methods CCND1 amplification was assessed using SNP arrays from two cohorts of 1965 and 340 patients with matching gene expression array and clinical follow-up data of over 15 years. Kaplan-Meier and multivariable Cox regression analyses were used to determine survival differences between CCND1 amplified vs. non-amplified tumours in clinically relevant patient sets, within PAM50 subtypes and within treatment-specific subgroups. Boxplots and differential gene expression analyses were performed to assess differences between amplified vs. non-amplified tumours within PAM50 subtypes. Results When combining both cohorts, worse survival was found for patients with CCND1-amplified tumours in luminal A (HR = 1.68; 95% CI, 1.15–2.46), luminal B (1.37; 1.01–1.86) and ER+/LN−/HER2− (1.66; 1.14–2.41) subgroups. In gene expression analysis, CCND1-amplified luminal A tumours showed increased proliferation (P

Published
2019
Full Text
View/download PDF

3. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours

Author

Theodoros Foukakis, Emmanouil G. Sifakis, Charles M. Perou, Kamila Czene, Jonas Bergh, Linda S. Lindström, Eva Darai-Ramqvist, Arian Lundberg, Jingmei Li, J. Chuck Harrell, and Nicholas P. Tobin

Subjects
Oncology, Adult, medicine.medical_specialty, Receptor, ErbB-2, Breast Neoplasms, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Cyclin D1, Surgical oncology, CCND1 Gene Amplification, Predictive Value of Tests, Internal medicine, Gene expression, Gene duplication, medicine, Biomarkers, Tumor, CDK4/6, Humans, Genetic Testing, CCND1 gene amplification, PAM50, BCSS, Retrospective Studies, Proportional hazards model, business.industry, Gene Amplification, Middle Aged, medicine.disease, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Survival Analysis, 3. Good health, Luminal A, Receptors, Estrogen, 030220 oncology & carcinogenesis, Biomarker (medicine), Female, Lymph Nodes, business, Follow-Up Studies, Research Article
Abstract

Background Use of cyclin D1 (CCND1) gene amplification as a breast cancer biomarker has been hampered by conflicting assessments of the relationship between cyclin D1 protein levels and patient survival. Here, we aimed to clarify its prognostic and treatment predictive potential through comprehensive long-term survival analyses. Methods CCND1 amplification was assessed using SNP arrays from two cohorts of 1965 and 340 patients with matching gene expression array and clinical follow-up data of over 15 years. Kaplan-Meier and multivariable Cox regression analyses were used to determine survival differences between CCND1 amplified vs. non-amplified tumours in clinically relevant patient sets, within PAM50 subtypes and within treatment-specific subgroups. Boxplots and differential gene expression analyses were performed to assess differences between amplified vs. non-amplified tumours within PAM50 subtypes. Results When combining both cohorts, worse survival was found for patients with CCND1-amplified tumours in luminal A (HR = 1.68; 95% CI, 1.15–2.46), luminal B (1.37; 1.01–1.86) and ER+/LN−/HER2− (1.66; 1.14–2.41) subgroups. In gene expression analysis, CCND1-amplified luminal A tumours showed increased proliferation (P

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results